Outrun Therapeutics, a pioneering force in E3 ligase inhibition and protein stabilization, has announced its emergence from stealth mode, bolstered by a substantial $10 million seed financing round. The company’s innovative platform has swiftly generated a robust pipeline of highly selective, small molecule, first-in-class E3 ligase inhibitors, alongside the discovery of novel E3 ligase targets…